72 Pa. Stat. § 3761-705

Current through Pa Acts 2024-35, 2024-56
Section 3761-705 - Amount of rebate
(a) Single-source drugs and innovator multiple-source drugs.--With respect to single-source drugs and innovator multiple-source drugs, each manufacturer shall remit a rebate to the Commonwealth. Except as otherwise provided in this section, the amount of the rebate to the Commonwealth per calendar quarter with respect to each dosage form and strength of single-source drugs and innovator multiple-source drugs shall be as follows:
(1) For quarters beginning after September 30, 1992, and ending before January 1, 1997, the product of the total number of units of each dosage form and strength reimbursed by PACE and General Assistance in the quarter and the difference between the average manufacturer price and 85% of that price, after deducting customary prompt payment discounts, for the quarter.
(2) For quarters beginning after December 31, 1996, and ending before January 1, 2003, the product of the total number of units of each dosage form and strength reimbursed by PACE, PACENET and designated pharmaceutical programs in the quarter and the difference between the average manufacturer price and 83% of that price, after deducting customary prompt payment discounts.
(3) For quarters beginning after December 31, 2002, each manufacturer shall remit a rebate to the Commonwealth for the total number of units of each dosage form and strength reimbursed by PACE, PACENET and designated pharmaceutical programs in the quarter pursuant to the determination established by section 1927(c)(1) of the Social Security Act (49 Stat. 620, 42 U.S.C. § 1396r - 8(c)(1) ).
(b) Rebate for other drugs.--
(1) The amount of the rebate to the Commonwealth for a calendar quarter with respect to covered prescription drugs which are noninnovator multiple-source drugs shall be equal to the product of:
(i) the applicable percentage of the average manufacturer price, after deducting customary prompt payment discounts, for each dosage form and strength of such drugs for the quarter; and
(ii) the number of units of such form and dosage reimbursed by PACE and General Assistance in the quarter.
(2) For the purposes of paragraph (1), the applicable percentage for calendar quarters beginning after September 30, 1992, and ending before January 1, 1997, is 11%.
(c) Revised rebate for other drugs.--Beginning after December 31, 1996, and ending before January 1, 2004, all of the following shall apply:
(1) The amount of the rebate to the Commonwealth for a calendar quarter with respect to covered prescription drugs which are noninnovator multiple-source drugs shall be the greater of the product of:
(i) The applicable percentage of the average manufacturer price, after deducting customary prompt payment discounts, for each dosage form and strength of such drugs for the quarter; and
(ii) the number of units of such form and dosage reimbursed by PACE, PACENET and designated pharmaceutical programs in the quarter.
(2) For purposes of paragraph (1), the applicable percentage is 17%.
(c.1) Rebates for other drugs.--For quarters beginning after December 31, 2003, each manufacturer shall remit a rebate to the Commonwealth for the total number of units of each dosage form and strength reimbursed by PACE, PACENET and designated pharmaceutical programs in the quarter pursuant to the determination established by section 1927(c)(3) of the Social Security Act (49 Stat. 620, 42 U.S.C. § 1396r - 8(c)(3) ).
(d) Drugs approved after act takes effect.--In the case of a covered outpatient drug approved for marketing after the effective date of the act of August 14, 1991 (P.L. 342, No. 36), known as the Lottery Fund Preservation Act, any reference to January 1, 1991, shall be a reference to the first day of the first month during which the drug was marketed.

72 P.S. § 3761-705

1971, Aug. 26, P.L. 351, No. 91, § 705, added 1996, Nov. 21, P.L. 741, No. 134, § 2, imd. effective. Amended 2003, Nov. 26, P.L. 212, No. 37, § 9, imd. effective; 2004, Nov. 30, P.L. 1722, No. 219, § 2, imd. effective.